P. Baumann

Publications374
h-index58
Citations10,754
Highly Influential Citations376
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • C. Hiemke
  • 595 Publications • 14,024 Citations
  • C. Eap
  • 254 Publications • 8,132 Citations
  • L. Bertilsson
  • 391 Publications • 25,245 Citations
  • D. Greenblatt
  • 1,355 Publications • 60,222 Citations
  • Publications
  • Influence
AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.
TLDR
Following guidelines for TDM in psychiatry will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems, and one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data. Expand
Interindividual Variability of the Clinical Pharmacokinetics of Methadone
TLDR
Because of the high morbidity and mortality associated with opioid dependence, it is of major importance that methadone is used at an effective dosage in maintenance treatment: at least 60 mg/day, but typically 80–100 mg/ day. Expand
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
TLDR
Following the new guidelines for therapeutic drug monitoring in psychiatry holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs. Expand
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.
Therapeutic Drug Monitoring (TDM) is a valid tool to optimise pharmacotherapy. It enables the clinician to adjust the dosage of drugs according to the characteristics of the individual patient. In… Expand
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
TLDR
This work aimed to determine the influence of CYP2B6, CYP 2C9, and CYP1C19 genetic polymorphism on methadone pharmacokinetics and on the response to treatment. Expand
ABCB1 and Cytochrome P450 Polymorphisms: Clinical Pharmacogenetics of Clozapine
TLDR
This study has shown for the first time a significant in vivo role of CYP2C19 and the P-gp transporter in the pharmacokinetics of clozapine. Expand
Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity
  • C. Eap, T. Buclin, +8 authors R. Kerb
  • Chemistry, Medicine
  • European Journal of Clinical Pharmacology
  • 28 April 2004
TLDR
A low oral dose of midazolam can be used to measure the in vivo CYP3A activity, either by the determination of total 1′OH-midZolam/midazol am ratios at 30 min or by thedetermination of midAZolam plasma levels between 1.5 h and 4 h after its administration. Expand
The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
TLDR
This study shows that CYP2D6 catalyses the metabolism of R- and S-fluoxetine and most likely the further metabolism of S-norflu oxetine but not of R -norfluxetine. Expand
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.
TLDR
Following guidelines for TDM in psychiatry will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems, and one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data. Expand
Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors
  • P. Baumann
  • Medicine
  • Clinical pharmacokinetics
  • 1 December 1996
TLDR
No clearcut plasma concentration-clinical effectiveness relationship in patients with depression has been shown, nor any threshold which defines toxic concentrations, and SSRIs presently available may be explained by their low toxicity and use at dosages where serious adverse effects do not appear. Expand
...
1
2
3
4
5
...